Table 3 Next generation clinical CAR-T therapy.
From: CAR-T therapy dilemma and innovative design strategies for next generation
Challenge | Strategies | Targets | Design | Identifiers |
|---|---|---|---|---|
Lethal cytotoxicity | Self-control | Mesothelin | Transfecting T cells with mRNA encoding an anti-mesothelin CAR | NCT01355965, NCT01897415 |
CD19 | Tuning the affinity of CAR to CD19 | NCT02443831 | ||
Active-control | CD44v6 | Coexpressing the suicide gene HSV-TK Mut2 and CAR CD44v6 | NCT00423124 | |
GD2 | Transducing T cells with 14g2a-CD8-BBz-iCasp9 retroviral vector expressing GD2-CAR | NCT04196413 | ||
Restricted trafficking and limited tumor infiltration | Chemokine-based CAR-T-cell enrichment | BCMA | Simultaneously expressing IL7 and CCL19 | NCT03778346 |
EGFR | CXCR5 modified EGFR-CAR-T cells | NCT05060796, NCT04153799 | ||
BCMA | CXCR4 modified BCMA-CAR-T cells | NCT04727008 | ||
CD70 | CXCR2 modified CD70-CAR-T cells | NCT05353530 | ||
Immunosuppressive microenvironment | Oncolytic viruses | HER2 | Combined injection of HER2-CAR-T cells and CAdVEC | NCT03740256 |
Mesothelin | Combined injection mesothelin-CAR-T cells and VCN-01 (expressing hyaluronidase) | NCT05057715 |
